尼非卡兰的临床应用

郭牧; 田树光; 宋昱

doi:10.13201/j.issn.1001-1439.2017.02.021

尼非卡兰的临床应用

- 天津医科大学临床心血管病学院泰达国际心血管病医院CCU(天津, 300457)

详细信息

通讯作者: 宋昱,E-mail:dr.songyu@163.com

中图分类号: R541.7

收稿日期: 2016-05-03

The clinical application of nifekalant

- Cardiac Care Unit, TEDA International Cardiovascular Hospital, Cardiovascular Clinical Institute, Tianjin Medical University, Tianjin, 300457, China

More Information

Corresponding author: SONG Yu, E-mail: dr.songyu@163.com

Received Date: 03 May 2016

摘要

摘要: 快速室性心动过速(VT)/心室颤动(VF)是大多数心脏性猝死(SCD)的原因。有效终止VT/VF是预防SCD的基本策略。对于结构性心脏病和(或)伴有心功能障碍及急性心肌梗死的患者,有效的治疗措施有限。目前国内迅速起效的注射用Ⅲ类抗心律失常药物只有胺碘酮,但其有低血压、肝功能障碍、乳酸酸中毒等禁忌证。注射用盐酸尼非卡兰是一种新型Ⅲ类抗心律失常药物,日本、欧洲指南中已有临床应用的推荐。详细了解该药物特点,对临床增加治疗手段尤为重要。
- 心律失常 /
- 尼非卡兰 /
- 临床应用
Abstract: Rapid ventricular tachycardia(VT)/ventricular fibrillation(VF) is the cause of most sudden cardiac death(SCD). Effective termination of VT and VF is the basic strategy to prevent SCD.However, for the patients with structural heart disease or with heart failure and acute myocardial infarction, the effective treatment is limited.Among the agents of fast acting injectable class Ⅲ antiarrhythmic drugs, only amiodarone is available in domestic. But amiodarone is contraindicated in patients with hypotension, liver dysfunction and lactic acidosis etc. Nifekalant hydrochloride for injection is a new class Ⅲ antiarrhythmic drug, which has been recommended in the clinical guidelines of Japan and Europe. Therefore, it is particularly important to understand the properties of this agent in detail for bringing in additional clinical treatment of VT and VF.
- arrhythmia /
- nifekalant /
- clinical application

HTML全文

参考文献(10)

[1]	ADABAG A S,LUEPKER R V,ROGER V L,et al.Sudden cardiac death:epidemiology and risk factors[J].Nat Rev Cardiol,2010,7:216-225.
[2]	中华医学会心血管病学分会,中国生物医学工程学会心律分会,中国医师协会循证医学专业委员会,中国老年学学会心脑血管病专业委员会,《心律失常紧急处理专家共识》专家工作组.心律失常紧急处理专家共识[J].中华心血管病杂志,2013,41(5):363-376.
[3]	KATOH T,MITAMURA H,MATSUDA N,et al.Emergency treatment with nifekalant,a novel classⅢanti-arrhythmic agent,for life-threatening refractory ventricular tachyarrhythmias:post-marketing special investigation[J].Circ J,2005,69:1237-1243.
[4]	AMINO M,YOSHIOKA K,KANDA S,et al.Systematic review of the use of intravenous amiodarone and nifekalant for cardiopulmonary resuscitation in Japan[J].J Arrhythm,2014,30:180-185.
[5]	HARAYAMA N,NIHEI S,NAGATA K,et al.Comparison of nifekalant and amiodaone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation[J].JAnesth,2014,28:587-592.
[6]	SHIGA T,TANAKA K,KATO R,et al.Nifekalant versus lidocaine for in-hospital shock-resistant ventricular fibrillation or tachycardia[J].Resuscitation,2010,81:47-52.
[7]	王靖,华伟,朱俊,等.长时间应用盐酸尼非卡兰治疗持续性室性心动过速的安全性与有效性分析[J].中华心律失常学杂志,2008,14(1):34-38.
[8]	WANG J,HUA W,ZHU J,et al.Nifekalant hydrochloride terminating sustained ventricular tachycardia accompanied with QT dispersion prolongation[J].Chin Med J,2010,123:2028-2033.
[9]	CALLAWAY C W,SOAR J,AIBIKI M,et al.Part 4:Advanced Life Support:2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations[J].Circulation,2015,132:S84-145.
[10]	SOAR J,NOLAN J P,BÖTTIGER B W,et al.European Resuscitation Council Guidelines for Resuscitation 2015:Section 3.Adult advanced life support[J].Resuscitation,2015,95:100-147.